Cyclin A2: Potential Drug Target and Biomarker for Various Diseases
Cyclin A2: Potential Drug Target and Biomarker for Various Diseases
Cyclin A2 (CCNA2) is a protein that plays a critical role in the regulation of cell division and growth. It is a key component of the G1 phase of the cell cycle, where the cell prepares for cell division by producing enough copies of its genetic material. Cyclin A2 is a 24-kDa protein that consists of two subunits, alpha and beta. This protein has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and mental disorders.
During the G1 phase of the cell cycle, the cell prepares for cell division by producing enough copies of its genetic material. The G1 phase is critical for the development and growth of the cell, and it is during this phase that the cell prepares to divide by producing new copies of its genetic material. Cyclin A2 is a key component of the G1 phase, and it plays a critical role in regulating the production of new copies of the genetic material.
Cyclin A2 is a 24-kDa protein that consists of two subunits, alpha and beta. The alpha subunit has a molecular weight of 42 kDa, and it is 10 kDa longer than the beta subunit. The alpha subunit has four potential binding sites, including a binding site for the protein p21, which is a transcription factor that plays a critical role in regulating cell growth and division. The beta subunit has two potential binding sites, including a binding site for the protein p53, which is a tumor suppressor protein that plays a critical role in regulating cell growth and division.
Cyclin A2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and mental disorders. For example, studies have shown that Cyclin A2 is overexpressed in various diseases, including cancer, neurodegenerative diseases, and mental disorders. disorders. This suggests that Cyclin A2 may be a useful target for these diseases.
In addition to its potential as a drug target, Cyclin A2 has also been identified as a biomarker for various diseases. For example, studies have shown that Cyclin A2 levels are elevated in individuals with depression, anxiety, and schizophrenia. This suggests that Cyclin A2 may be a useful biomarker for these diseases.
Cyclin A2 has also been shown to play a critical role in the regulation of cell growth and division. For example, studies have shown that Cyclin A2 is involved in the regulation of cell cycle progression, and that it plays a critical role in the G1 phase of the cell cycle. This suggests that Cyclin A2 may be a useful target for diseases that are characterized by abnormal cell division, such as cancer.
In conclusion, Cyclin A2 is a protein that plays a critical role in the regulation of cell division and growth. It is a key component of the G1 phase of the cell cycle, and it has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and mental disorders. Further research is needed to fully understand the role of Cyclin A2 in the regulation of cell division and growth, and to determine its potential as a drug target and biomarker.
Protein Name: Cyclin A2
Functions: Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle
The "CCNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNA2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244
